These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

179 related articles for article (PubMed ID: 35840162)

  • 21. Enriched HLA-E and CD94/NKG2A Interaction Limits Antitumor CD8
    Abd Hamid M; Wang RZ; Yao X; Fan P; Li X; Chang XM; Feng Y; Jones S; Maldonado-Perez D; Waugh C; Verrill C; Simmons A; Cerundolo V; McMichael A; Conlon C; Wang X; Peng Y; Dong T
    Cancer Immunol Res; 2019 Aug; 7(8):1293-1306. PubMed ID: 31213473
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Combination of PD-1 Checkpoint Blockade and Botulinum Toxin Type A1 Improves Antitumor Responses in Mouse Tumor Models of Melanoma and Colon Carcinoma.
    Kwak S; Lee JY; Kim MJ; Lee HJ; Lee DK; Kang J; Kang WH; Son WC; Cruz DJM
    Immunol Invest; 2023 Nov; 52(6):749-766. PubMed ID: 37403798
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Cocultures of human colorectal tumor spheroids with immune cells reveal the therapeutic potential of MICA/B and NKG2A targeting for cancer treatment.
    Courau T; Bonnereau J; Chicoteau J; Bottois H; Remark R; Assante Miranda L; Toubert A; Blery M; Aparicio T; Allez M; Le Bourhis L
    J Immunother Cancer; 2019 Mar; 7(1):74. PubMed ID: 30871626
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Assay of T- and NK-cell subsets and the expression of NKG2A and NKG2D in patients with new-onset systemic lupus erythematosus.
    Li WX; Pan HF; Hu JL; Wang CZ; Zhang N; Li J; Li XP; Xu JH; Ye DQ
    Clin Rheumatol; 2010 Mar; 29(3):315-23. PubMed ID: 20012119
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Targeting NKG2A to boost anti-tumor CD8 T-cell responses in human colorectal cancer.
    Ducoin K; Oger R; Bilonda Mutala L; Deleine C; Jouand N; Desfrançois J; Podevin J; Duchalais E; Cruard J; Benlalam H; Labarrière N; Bossard C; Jarry A; Gervois-Segain N
    Oncoimmunology; 2022; 11(1):2046931. PubMed ID: 35295095
    [TBL] [Abstract][Full Text] [Related]  

  • 26. In situ immunogenic clearance induced by a combination of photodynamic therapy and rho-kinase inhibition sensitizes immune checkpoint blockade response to elicit systemic antitumor immunity against intraocular melanoma and its metastasis.
    Kim S; Kim SA; Nam GH; Hong Y; Kim GB; Choi Y; Lee S; Cho Y; Kwon M; Jeong C; Kim S; Kim IS
    J Immunother Cancer; 2021 Jan; 9(1):. PubMed ID: 33479026
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Calcineurin-dependent negative regulation of CD94/NKG2A expression on naive CD8+ T cells.
    Cho JH; Kim HO; Webster K; Palendira M; Hahm B; Kim KS; King C; Tangye SG; Sprent J
    Blood; 2011 Jul; 118(1):116-28. PubMed ID: 21540458
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Targeted Delivery of IL2 to the Tumor Stroma Potentiates the Action of Immune Checkpoint Inhibitors by Preferential Activation of NK and CD8
    Hutmacher C; Gonzalo Núñez N; Liuzzi AR; Becher B; Neri D
    Cancer Immunol Res; 2019 Apr; 7(4):572-583. PubMed ID: 30782667
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Blockade of checkpoint receptor PVRIG unleashes anti-tumor immunity of NK cells in murine and human solid tumors.
    Li Y; Zhang Y; Cao G; Zheng X; Sun C; Wei H; Tian Z; Xiao W; Sun R; Sun H
    J Hematol Oncol; 2021 Jun; 14(1):100. PubMed ID: 34174928
    [TBL] [Abstract][Full Text] [Related]  

  • 30. NKG2A is a late immune checkpoint on CD8 T cells and marks repeated stimulation and cell division.
    Borst L; Sluijter M; Sturm G; Charoentong P; Santegoets SJ; van Gulijk M; van Elsas MJ; Groeneveldt C; van Montfoort N; Finotello F; Trajanoski Z; Kiełbasa SM; van der Burg SH; van Hall T
    Int J Cancer; 2022 Feb; 150(4):688-704. PubMed ID: 34716584
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Intralesional administration of VAX014 facilitates in situ immunization and potentiates immune checkpoint blockade in immunologically cold tumors.
    Reil KA; Tsuji S; Molina E; Nelson KL; McGuire KL; Giacalone MJ
    J Immunother Cancer; 2023 Jun; 11(6):. PubMed ID: 37290924
    [TBL] [Abstract][Full Text] [Related]  

  • 32. PI3Kαδ Inhibitor Combined With Radiation Enhances the Antitumor Immune Effect of Anti-PD1 in a Syngeneic Murine Triple-Negative Breast Cancer Model.
    Chang WI; Han MG; Kang MH; Park JM; Kim EE; Bae J; Ahn S; Kim IA
    Int J Radiat Oncol Biol Phys; 2021 Jul; 110(3):845-858. PubMed ID: 33642128
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Newly emerged immunogenic neoantigens in established tumors enable hosts to regain immunosurveillance in a T-cell-dependent manner.
    Muramatsu T; Noguchi T; Sugiyama D; Kanada Y; Fujimaki K; Ito S; Gotoh M; Nishikawa H
    Int Immunol; 2021 Jan; 33(1):39-48. PubMed ID: 32729901
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Skin dendritic cells in melanoma are key for successful checkpoint blockade therapy.
    Prokopi A; Tripp CH; Tummers B; Hornsteiner F; Spoeck S; Crawford JC; Clements DR; Efremova M; Hutter K; Bellmann L; Cappellano G; Cadilha BL; Kobold S; Boon L; Ortner D; Trajanoski Z; Chen S; de Gruijl TD; Idoyaga J; Green DR; Stoitzner P
    J Immunother Cancer; 2021 Jan; 9(1):. PubMed ID: 33408092
    [TBL] [Abstract][Full Text] [Related]  

  • 35. PD-1 blockade synergizes with intratumoral vaccination of a therapeutic HPV protein vaccine and elicits regression of tumor in a preclinical model.
    Peng S; Tan M; Li YD; Cheng MA; Farmer E; Ferrall L; Gaillard S; Roden RBS; Hung CF; Wu TC
    Cancer Immunol Immunother; 2021 Apr; 70(4):1049-1062. PubMed ID: 33108473
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Response to Programmed Cell Death-1 Blockade in a Murine Melanoma Syngeneic Model Requires Costimulation, CD4, and CD8 T Cells.
    Homet Moreno B; Zaretsky JM; Garcia-Diaz A; Tsoi J; Parisi G; Robert L; Meeth K; Ndoye A; Bosenberg M; Weeraratna AT; Graeber TG; Comin-Anduix B; Hu-Lieskovan S; Ribas A
    Cancer Immunol Res; 2016 Oct; 4(10):845-857. PubMed ID: 27589875
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Structure of the murine CD94-NKG2A receptor in complex with Qa-1
    MacLachlan BJ; Sullivan LC; Brooks AG; Rossjohn J; Vivian JP
    FEBS J; 2024 Apr; 291(7):1530-1544. PubMed ID: 38158698
    [TBL] [Abstract][Full Text] [Related]  

  • 38. PD-L1 targeting high-affinity NK (t-haNK) cells induce direct antitumor effects and target suppressive MDSC populations.
    Fabian KP; Padget MR; Donahue RN; Solocinski K; Robbins Y; Allen CT; Lee JH; Rabizadeh S; Soon-Shiong P; Schlom J; Hodge JW
    J Immunother Cancer; 2020 May; 8(1):. PubMed ID: 32439799
    [TBL] [Abstract][Full Text] [Related]  

  • 39.
    Cheng Y; Lemke-Miltner CD; Wongpattaraworakul W; Wang Z; Chan CHF; Salem AK; Weiner GJ; Simons AL
    J Immunother Cancer; 2020 Oct; 8(2):. PubMed ID: 33060147
    [TBL] [Abstract][Full Text] [Related]  

  • 40. The NKG2A-HLA-E Axis as a Novel Checkpoint in the Tumor Microenvironment.
    Borst L; van der Burg SH; van Hall T
    Clin Cancer Res; 2020 Nov; 26(21):5549-5556. PubMed ID: 32409305
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.